Project Grant R01AI192307
Award Date 8/26/26
Completion Date 7/31/30
Dollars Obligated $699K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Urbana, IL 61801, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $236,407 on September 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the structural basis of ARMA-mediated resistance to aminoglycoside antibiotics targeting the bacterial ribosome. The research addresses how ARMA methyltransferases confer high-level resistance to aminoglycosides—a cornerstone class of ribosome-binding antibacterial drugs used...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $440,908 on February 3, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to identify inhibitors of bacterial peptidyl-tRNA hydrolase (PTH). The recipient will synthesize and optimize derivatives of PTH inhibitor compounds with sub-micromolar IC50 values to enhance their activity against Klebsiella pneumoniae PTH and improve cellular uptake. The work includes expanding...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $790,913 on July 13, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to define the molecular and cellular mechanisms by which gut commensal microbiota-specific T cells drive intestinal and neuroinflammation. The project investigates how segmented filamentous bacteria (SFB)-specific CD4 T cells, initially generated in gut-draining mesenteric lymph nodes and intestines in...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $3,068,770 on August 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop neuraminidase-based influenza vaccines with broad protective immunity. The research systematically analyzes the structure-function relationships of neuraminidase monoclonal antibodies, maps the affinity maturation pathways leading to broadly protective antibodies, and engineers a broadly...
- The National Institute of Allergy and Infectious Diseases awarded the University of Virginia $795,313 on August 10, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on subcellular definition of accumulation in Escherichia coli as a strategy to address antimicrobial resistance. The research seeks to formulate foundational principles governing molecular characteristics that define cellular penetration in bacteria, similar to Lipinski's Rule of Five...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded the University of Illinois $200,413 on August 5, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for Project Grant R21AI193553. The award funds research targeting GPR15, a chemoattractant receptor implicated in inflammatory bowel disease pathology. The research seeks to develop reagents and approaches to specifically modulate GPR15 activity as a...
- Federal Project Grant Award Summary The University of Illinois received a $456,911 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) for the period July 1, 2025 through June 30, 2027. The award supports research focused on developing innovative antibiotic combination therapies to treat multidrug-resistant hypervirulent Klebsiella pneumoniae (MDR-HVKP), a bacterial pathogen that causes...
- The National Institute of Allergy and Infectious Diseases awarded Northern Illinois University $147,766 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on September 3, 2026. The award funds research investigating how geminivirus viral RNA silencing suppressors (AC2/C2 proteins) subvert the SNRK1/autophagy pathway to suppress host plant antiviral immune responses. The research addresses geminivirus crop disease control by examining defense-counterdefense interactions at...
- The National Institute of Allergy and Infectious Diseases, part of the Department of Health and Human Services, awarded $571,412 to the University of Maryland, College Park on June 11, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research into the regulation of bacterial physiology and infections through linear diribonucleotides and RNA degradation. The project will characterize how diribonucleases and triribonucleases bind their respective...
- The National Institute of Allergy and Infectious Diseases awarded the University of Illinois $736,822 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate how bacterial lipases drive host immunity and physiology during infection. The research focuses on Staphylococcus aureus lipases, particularly the secreted lipase GEH, which the recipient's laboratory has shown inhibits activation of innate immune cells and blunts pro-inflammatory...